Description

Volixibat Potassium is a potent and selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT). This compound is a critical active pharmaceutical ingredient (API) in the development of novel therapeutics targeting cholestatic liver diseases and related metabolic disorders. It is primarily utilized by pharmaceutical manufacturers and research institutions engaged in the development of treatments for conditions like primary biliary cholangitis (PBC) and Alagille syndrome. The product is supplied to meet the stringent quality and reliability demands of the global pharmaceutical supply chain.

Application

• Pharmaceutical API: Primary use as the active ingredient in clinical and commercial drug formulations targeting bile acid-mediated disorders.
• Clinical Research: Serves as a key reference standard and investigational compound in preclinical and clinical trials for liver diseases.
• Metabolic Disorder Studies: Used in biochemical research to study bile acid metabolism, intestinal absorption, and related pathways.
• Drug Development: Integral to the R&D pipeline for novel ASBT inhibitors, supporting formulation development and stability studies.
• Contract Manufacturing: Supplied to CDMOs (Contract Development and Manufacturing Organizations) for the production of finished dosage forms.

Basic Information

Product Name	Volixibat Potassium
CAS No.	220334-14-5
Molecular Formula	C29H33F3N2O6S2K
Molecular Weight	665.81 g/mol
Synonyms	Volixibat Potassium Salt; SHP626 Potassium; (1R,3r,5S)-8-({(3R,4R,5R)-3-Butyl-3-ethyl-7-(methylsulfonyl)-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl}carbonyl)-8-azabicyclo[3.2.1]octan-3-yl 2,3,4-tris-O-(phenylcarbonyl)-β-D-glucopyranosiduronate Potassium Salt; ASBT Inhibitor SHP626; LX-4210 Potassium; GSK-2330672 Potassium
EINECS	Contact for details

Quality Control

Our Volixibat Potassium is manufactured under strict quality systems to ensure it meets the high-purity standards required for pharmaceutical applications. Each batch is accompanied by a comprehensive Certificate of Analysis (COA) detailing purity, identity, and impurity profiles. We adhere to cGMP (current Good Manufacturing Practice) guidelines, and our quality control protocols are designed to support regulatory filings for investigational and commercial drug products.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). This material is hygroscopic (moisture-sensitive) and must be kept under inert atmosphere or in a desiccated environment to maintain stability and potency. Keep away from incompatible materials.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (HPLC)	Conforms to reference standard
Identification (IR)	Conforms to structure
Assay (HPLC)	≥ 98.0%
Water Content (KF)	≤ 2.0%
Residue on Ignition	≤ 0.5%
Heavy Metals	≤ 20 ppm
Related Substances (HPLC)	Individual impurity ≤ 0.5%; Total impurities ≤ 2.0%
Residual Solvents (GC)	Complies with ICH Q3C guidelines

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.